In this study, the expression of ACTL6A gene in chemoresistant and metastatic ovarian cancer was mined, we and further performed a drug screening based on ACTL6A expression in different ovarian cancer cells, which provided the potential association of high ACTL6A expression levels with the good response of CP724714, a human epidermal growth factor receptor 2 (HER2) inhibitor, discovered through Q-omics software analysis. The gene discussed is ERBB2; the disease is ovarian cancer.